Merck: new research agreement with Starpharma

(CercleFinance.com) - Australian biotech company Starpharma announced Wednesday that it has signed a new research agreement with US biopharmaceutical giant Merck in the field of antibody conjugates.


The partnership aims to identify and evaluate new drugs from the Melbourne-based company's "DEP" technology platform.

Antibody-drug conjugates (ADCs) are an increasingly preferred class of therapeutic agents in oncology due to their ability to provide targeted therapy with minimal toxicity.

According to Starpharma, its DEP technology enables precise binding of the armed antibody, with a more selective and homogeneous mechanism compared to currently available products.


Copyright (c) 2022 CercleFinance.com. All rights reserved.